Giuseppe Andò: Stable CAD + Oral Anticoagulation: Is Combination Therapy Still Justified?
Giuseppe Andò, Head of the Cardiology Department at Papardo University Hospital, shared on LinkedIn:
” Stable CAD + Oral Anticoagulation: Is Combination Therapy Still Justified?
For years, adding antiplatelet therapy to oral anticoagulation has been considered “safer.”
The evidence no longer supports this approach.
In the post-AQUATIC era, leveraging data from a large European RCT that expanded indications for OAC beyond atrial fibrillation, we conducted an updated meta-analysis of 6 randomized trials (n = 5,924) comparing OAC monotherapy vs OAC + SAPT in stable coronary artery disease.
OAC monotherapy delivers:
−51% major bleeding
Lower net adverse clinical events
Reduced cardiovascular mortality
No increase in ischemic events
Even more compelling: DOAC-based monotherapy significantly reduced MACE, with a clear treatment interaction.
Bottom line:
In patients with stable CAD requiring long-term anticoagulation, less is more.
OAC monotherapy—particularly with DOACs—should be the default strategy, especially in East Asian populations.
After AQUATIC, continuing routine combination therapy deserves serious reconsideration.”
Title: Oral anticoagulation with versus without antiplatelet therapy in patients with stable coronary artery disease and an indication for anticoagulation: a meta-analysis with trial sequential analysis
Authors: Ahmed Ibrahim, Ali Saad Al-Shammari, Shrouk Ramadan, Yousif Hameed Kurmasha, Khadeeja Ali Hamzah, M Rafiqul Islam, Muhammad Younas, Hritvik Jain, Yasar Sattar, Pierre Sabouret and Giuseppe Andò.
Read the full article.
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications